Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,310 total articles
Micron's business is capturing robust AI memory demand, generating meaningful free cash flow, and trading well above its multi-year lows. Valuation looks rich versus history but is supported by strong profitability and low leverage. This trade idea sets a long-term (180 trading days) plan with entry at $760, target $1,000 and a stop at $650 to bala…
Southern Company (SO) combines a conservative regulated utility base with growing wholesale and gas platforms that stand to benefit from accelerated data center and AI-related electricity demand. Recent beats, reaffirmed guidance, and a visible dividend raise underscore operational resilience. Valuation is not cheap for a utility, but rate-base exp…
United Microelectronics (UMC) is showing the technical, strategic and sentiment signs of a re-rating. Recent IP deals around hybrid bonding, a U.S. 8-inch collaboration and merger chatter have shifted investor expectations away from a low-growth, mature-node foundry story. This trade recommends a measured long with an entry at the current level, a …
Alphabet is not SpaceX, but for investors who want pre-IPO exposure to the private space economy without illiquidity or lock-ups, buying Alphabet shares is a defensible, actionable strategy. Alphabet's scale, cash generation, cloud franchise and 'Other Bets' optionality make it a plausible conduit for indirect upside if a SpaceX IPO or strategic pa…
Hercules Capital (HTGC) is trading near $15.52 after a headline-driven sell-off. The stock yields roughly 10% on the current distribution cadence, trades at ~P/E 8.6 and P/B ~1.31, and sits well below its 52-week high. We lay out a mid-term trade plan to buy the dip with a clear entry, stop and target, and discuss the key risks — including active l…
argenx's FcRn platform (VYVGART and Hytrulo) is transitioning from a single blockbuster to a multi-indication backbone across neuromuscular and peripheral autoimmune diseases. FDA label expansion, strong Phase 3 readouts, and a clear commercial ramp argue for continued upside from today's $817 share price, but execution and competition keep risk el…
Rocket Lab (RKLB) has a rare alignment of fundamentals, backlog growth and market sentiment as SpaceX prepares to IPO. The technical setup is constructive and short-interest dynamics amplify upside. This trade plan lays out a clear entry at $129.62, a stop at $110.00 and a primary target of $170.00 over a mid-term 45 trading day horizon.
Arista's Q1 beat, raised AI revenue target and strong free cash flow argue that the recent selloff over margin pressure is an opportunity. This trade idea targets a bounce back toward prior highs as AI data-center demand remains intact; entry $150.00, stop $138.00, target $180.00, mid-term horizon (45 trading days).
Paramount-Skydance (PARA) is positioned to accelerate subscriber and advertising momentum after combining a deep content library with Skydance's production capabilities. We outline an actionable swing trade: entry $22.50, stop $19.00, target $28.00, with a longer-term upside target at $35.00 if execution and monetization accelerate.
VEON trades at a sub-$4B market cap with a P/E of ~7.3 and growing digital revenues ($759M in 2025). The stock offers an asymmetric risk-reward if you accept frontier-country execution and macro risk. This trade lays out entry, stop and target with a 180-trading-day horizon and clear rules for when the thesis fails.
Zymeworks ($ZYME) combines royalty revenue from licensed assets with a deep antibody-drug conjugate (ADC) pipeline that now carries real clinical momentum. The market prices the company like a high-growth commercial biopharma at a $1.85B market cap, but cash-like royalties, recent leadership hires aligned with deal execution, and Fast Track status …
Pfizer is trading at a reasonable valuation with a 6.7% yield, solid free cash flow and manageable leverage. Political talk of aggressive drug pricing reform has cooled, and the company’s pipeline (notably pneumococcal vaccines) plus accretive M&A optionality give a clear path to upside. We recommend a mid-term long with an entry at current levels,…
Flowers Foods' recent dividend reset and ugly near-term earnings have already been priced into the shares. The cut reduces cash bleed, gives management breathing room after the Simple Mills acquisition and a fiscal 2026 loss, and leaves the stock trading at cheap multiples and an oversold technical profile. I view this as a tactical long: enter at …
Microsoft is inexpensive relative to its moat in cloud and productivity if AI monetization follows through. Fundamentals (PE ~25, FCF ~$72.9B) and a $3.1T market cap imply patience; I lay out an actionable long with entry, stop and target and a 180-trading-day horizon to let enterprise AI traction show up in results.
Ciena has re-rated sharply on AI/data-center enthusiasm: revenue and earnings acceleration plus a $7 billion backlog have driven the stock to roughly $590 and a market cap near $83 billion. Fundamentals are improving, but valuation metrics - P/E near 350-360x, EV/EBITDA north of 200x and EV/Sales ~16x - imply expectations that leave little margin f…
Lyft is trading at bargain multiples relative to its cash generation and recent operational progress. With $1.1B in trailing free cash flow, $5.1B market cap and improving Adjusted EBITDA, the risk/reward for a mid-term swing long looks favorable. This trade idea lays out entry, stop and target, the fundamental case, catalysts and what will change …
Choice Hotels (CHH) is an asset-light franchisor with a clean cash profile and improving operational levers. Recent moves toward AI-enabled revenue management and cost automation, combined with a high short-interest backdrop and an attractive EV/EBITDA of 13.9x, create an asymmetric risk/reward. We upgrade to Positive and outline a concrete long tr…
ServiceNow is often painted as a legacy workflow vendor vulnerable to agentic AI. We argue the opposite: the Now Platform is the logical control point for enterprise agent orchestration and data governance. At $101.50 the stock offers a tradeable long with defined risk/reward as adoption of Now Assist and integrations (Cloudera, Experian) drive re-…
Lumentum has shifted from a niche photonics supplier into a core AI-data-center supplier. With Q3 revenue momentum, heavy buying interest from hyperscalers, and a clean product roadmap, LITE is my preferred pure-play on optical interconnects versus peers. This trade targets a mid-term run to $1,150 with a $840 stop—size accordingly given a richly p…
Keyera's midstream franchise still looks attractive after a pullback. Cheapening valuation and steady fee-based cash flow create a favorable asymmetric trade: enter at $47.50, protect at $42.00, and target $55.00 over a mid-term 45 trading day horizon.
Powell Industries (POWL) looks richly valued today at roughly $9.9B market cap and a P/E near 53, but a $1.6B backlog, double-digit order growth and near-net-cash balance sheet reduce execution risk. For disciplined traders I see a mid-term (45 trading days) long setup with a clear entry, stop and target that balances upside from backlog conversion…
Autohome (ATHM) faces revenue pressure from China’s car price wars, but a strong balance sheet, an attractive dividend yield (~10.3%), and a sub-1.0 PB multiple make the stock a tactical long for investors willing to accept execution risk. We lay out a mid-term swing plan with clear entry, target and stop-loss levels and a list of catalysts and ris…
Uber is trading at $73.70 with a $149.9B market cap and a free cash flow run-rate north of $9.1B. The company is uniquely positioned to monetize autonomy, delivery and logistics as an integrated platform. This trade targets the re-rating that comes from meaningful autonomous deployments, margin expansion and AI-driven efficiency gains.
NMI Holdings (NMIH) trades at a low-teens return on equity and single-digit P/E with a strong capital position and rising book value. Even if near-term earnings have peaked, the stock offers asymmetric upside from multiple expansion and continued book-value growth. Enter a disciplined long with a clear stop and target over a multi-month horizon.
USPH reported record Q1 revenue and reiterated full-year adjusted EBITDA guidance while absorbing non-cash accounting noise that hurt reported net income. The combination of $66.7M in free cash flow, a low-leverage balance sheet and an enlarged $450M credit facility argues the business is fundamentally intact. The market has largely priced the name…
